How much weight did each retatrutide dose produce?

In the Phase 3 TRIUMPH-1 obesity trial at 80 weeks, mean body-weight reduction was about 17.6% on 4 mg, 23.7% on 9 mg, and 25.0% on 12 mg, versus 3.9% on placebo. About 45% of the 12 mg group reached 30% or more weight loss, and participants with higher baseline BMI who continued 12 mg to 104 weeks averaged roughly 30% (about 85 lb). In the earlier Phase 2 trial, 12 mg produced about 24.2% at 48 weeks.

Educational · Investigational compound

Retatrutide dosing & titration

Q: What is the retatrutide dose escalation schedule?

The Phase 3 TRIUMPH program used a weekly subcutaneous escalation that steps up roughly every four weeks: 2 mg to start, then 4 mg, 6 mg, 9 mg, and a 12 mg maximum, with the target maintenance dose (for example 8, 9, or 12 mg) reached over several months. The earlier Phase 2 trial used a related 1/2/4/8/12 mg set of arms. Escalation is deliberately slow to limit gastrointestinal side effects. Retatrutide is investigational and not FDA-approved, so there is no official label schedule; these are trial protocols, not a prescription.

Q: Why is retatrutide titrated so slowly?

Like other incretin therapies, retatrutide's dose-limiting side effects are gastrointestinal - nausea, vomiting, diarrhea, and constipation - which are worst right after a dose increase. Slow, stepwise escalation lets the gut adapt and keeps most people on therapy. In the trials, escalation could be paused or a step delayed when side effects were significant. Pushing the dose faster than tolerance mostly buys more nausea, not more or faster weight loss.

Q: What is the maximum retatrutide dose?

The highest dose studied in the pivotal Phase 3 obesity trials is 12 mg once weekly, which also produced the largest weight loss. Some trial designs used 8 mg or 9 mg as a maintenance target for people who did not need or tolerate the top dose. There is no approved maximum because retatrutide is not yet approved.

Q: How do you reconstitute compounded retatrutide?

Compounded retatrutide is sold as a lyophilized powder in vials of varying strength (commonly 5, 10, 12, or 30 mg). You add a measured volume of bacteriostatic water to reach a known concentration, then draw the weekly dose on a U-100 insulin syringe. For example, a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, so a 2 mg dose is 0.2 mL (20 units). Concentrations vary by vial, so always compute from your own vial's stated strength - a reconstitution calculator does this arithmetic.

Retatrutide (Eli Lilly's LY3437943) is the triple-agonist injectable that produced the largest weight-loss numbers yet seen in obesity trials. This is a plain, evidence-graded look at how it was actually dosed in the Phase 3 TRIUMPH program - the weekly escalation, what each dose delivered, and why titration is paced by side effects. Retatrutide is investigational and not FDA-approved; this explains the trial protocols, it is not a prescription.

By OptiPin Editorial·Last updated July 2026

Trial escalation

2→4→6→9→12 mg

12 mg at 80 wk

~25% loss

Mechanism

Triple agonist

Dosing pace

Weekly, ~4-wk steps

TL;DR

• Escalation, not a fixed dose. TRIUMPH stepped weekly injections up roughly every four weeks: 2 → 4 → 6 → 9 → 12 mg.
• Dose tracks weight loss. At 80 weeks: ~17.6% (4 mg), ~23.7% (9 mg), ~25.0% (12 mg) vs 3.9% placebo ^[2].
• Titration is GI-gated. Nausea peaks after each step-up; slow escalation is what keeps people on therapy.
• Glucagon is the third lever. Adding glucagon-receptor activity drives hepatic fat oxidation and energy expenditure on top of GLP-1/GIP.
• It is not approved. No label, no official maximum - the numbers here are trial data, and dosing decisions belong with a clinician.

What retatrutide is, in one paragraph

Retatrutide is a once-weekly injectable that activates three receptors at once: GLP-1 and GIP (the two that tirzepatide hits) plus the glucagon receptor. The GLP-1 and GIP arms suppress appetite and slow gastric emptying; the glucagon arm raises energy expenditure and pushes hepatic fat oxidation, which appears to be why the triple agonist reaches higher weight-loss ceilings than dual or single agonists ^[1]. The concurrent GLP-1/GIP activity offsets glucagon's tendency to raise blood sugar, so glycemic control held in the trials. It is developed by Eli Lilly and, as of 2026, is in Phase 3 - not yet approved.

The TRIUMPH dose-escalation schedule

The pivotal Phase 3 TRIUMPH program used a stepwise weekly escalation designed to reach a high maintenance dose slowly. The steps move up about every four weeks:

Step	Weekly dose	Typical window	Purpose
1	2 mg	~weeks 1-4	Introduction, gut adaptation
2	4 mg	~weeks 5-8	First therapeutic step
3	6 mg	~weeks 9-12	Build-up
4	9 mg	~weeks 13-16	Maintenance target for many
5	12 mg	~week 17+	Maximum studied dose

Two caveats. The earlier Phase 2 trial used a slightly different arm set (1, 2, 4, 8, and 12 mg), which is why some older references cite an "8 mg" step; the Phase 3 program refined it toward the 2/4/6/9/12 ladder above ^[1]. And the "typical window" is illustrative - the actual pace in the trials could be held longer at a step if side effects warranted it. Not everyone climbs to 12 mg; 8-9 mg was a deliberate maintenance target for people who reached their goal or hit tolerance earlier.

What each dose actually delivered

The dose-response is unusually clean, higher dose, more weight loss. From TRIUMPH-1 (obesity/overweight) at 80 weeks ^[2]^[3]:

Dose	Mean weight loss (80 wk)	Notable
Placebo	~3.9%	Reference arm
4 mg	~17.6%	Low maintenance still substantial
9 mg	~23.7%	Common maintenance target
12 mg	~25.0%	~45% of this arm hit ≥30% loss

Longer and heavier: participants with a baseline BMI of 35+ who stayed on 12 mg through 104 weeks averaged about 30.3% (~85 lb) ^[3]. In the earlier Phase 2 read at 48 weeks, 12 mg produced about 24.2% ^[1]. For context, that Phase 2 figure edged out published tirzepatide data (~20-22%) in cross-trial comparison, which is the basis for retatrutide's "most powerful yet" framing, though no head-to-head trial has been completed. The comparison is covered in retatrutide vs tirzepatide.

Why titration is paced by side effects

Retatrutide's dose-limiting effects are gastrointestinal, nausea, vomiting, diarrhea, and constipation, and they are worst in the days right after a step-up. The entire point of the slow ladder is to let the gut adapt at each level before adding more. In the trials, escalation could be paused, and a step could be delayed or repeated, when side effects were significant. The practical lesson runs counter to intuition: climbing faster than your tolerance does not buy faster weight loss, it mostly buys more nausea and a higher chance of quitting. Hold a step until it is comfortable; only then move up.

Reconstitution reality (compounded retatrutide)

Because retatrutide is not an approved finished product, people using it are typically reconstituting a lyophilized powder from a vial, commonly labeled 5, 10, 12, or 30 mg. The math is the same as any peptide: add a measured volume of bacteriostatic water to reach a known concentration, then draw the weekly dose on a U-100 insulin syringe. A 10 mg vial with 1 mL of bacteriostatic water is 10 mg/mL, so a 2 mg dose is 0.2 mL (20 units); a 6 mg dose is 0.6 mL (60 units). Vial strengths and fill volumes vary, so always compute from your own vial, our reconstitution calculator does it for you, and the sourcing-quality caveats in the US peptide FDA status page apply.

The honest part

Retatrutide is an investigational drug, not FDA-approved, and has no official dosing label. Every figure above is trial data presented for education, not a protocol to copy, and gray-market or research-use-only supply carries real concentration, purity, and sterility risk. Incretin therapies also carry contraindications and monitoring needs (including thyroid C-cell tumor warnings in the class and pancreatitis signals). Do not start, escalate, or source retatrutide based on this page - dosing is a decision for you and a licensed clinician.

Track your titration on one timeline

OptiPin logs each retatrutide dose, forecasts your level between shots from real PK curves, flags when a step-up is due, and tracks how much vial supply is left, with a daily side-effect check-in so you can see whether the last step-up has settled before the next. iOS, on-device.

Download OptiPin

Frequently asked questions

What is the retatrutide dose escalation schedule?

The Phase 3 TRIUMPH program stepped weekly doses up roughly every four weeks: 2 → 4 → 6 → 9 → 12 mg, reaching a maintenance target (often 8-9 or 12 mg) over several months. Phase 2 used a 1/2/4/8/12 mg arm set. Escalation is slow to limit GI side effects. Retatrutide is not FDA-approved, so there is no official label schedule.

How much weight did each dose produce?

TRIUMPH-1 at 80 weeks: about 17.6% (4 mg), 23.7% (9 mg), and 25.0% (12 mg) vs 3.9% placebo; ~45% of the 12 mg arm reached ≥30% loss, and higher-BMI participants on 12 mg to 104 weeks averaged ~30% (~85 lb). Phase 2 showed ~24.2% at 48 weeks on 12 mg.

Why is retatrutide titrated so slowly?

Its dose-limiting side effects are gastrointestinal and peak right after each dose increase. Slow, stepwise escalation lets the gut adapt and keeps people on therapy; pushing faster than tolerance mostly adds nausea, not weight loss. Trials paused or delayed steps when side effects were significant.

What is the maximum retatrutide dose?

12 mg once weekly is the highest dose in the pivotal Phase 3 obesity trials, and it produced the most weight loss. Some designs used 8-9 mg as a maintenance target. There is no approved maximum because retatrutide is not yet approved.

How do you reconstitute compounded retatrutide?

Add a measured volume of bacteriostatic water to the powder vial to hit a known concentration, then draw on a U-100 syringe. A 10 mg vial + 1 mL water = 10 mg/mL, so 2 mg = 0.2 mL (20 units). Strengths vary; compute from your own vial with a reconstitution calculator.

Sources & further reading

Figures are from published Phase 2 and Phase 3 (TRIUMPH) results and vary by trial arm, population, and timepoint. Retatrutide is investigational; nothing here is a dosing recommendation.

Retatrutide side effects · Retatrutide reconstitution · Switching from tirzepatide · Retatrutide vs tirzepatide · Retatrutide + TRT · Retatrutide tracker · Retatrutide science · GLP-1 guide